What is Kflam?
Kflam is a nonsteroidal anti-inflammatory drug (NSAID). Kflam works by reducing hormones that cause inflammation and pain in the body.
Kflam is used short-term (5 days or less) to treat moderate to severe pain.
Kflam may also be used for purposes not listed in this medication guide.
Kflam indications
Carefully consider the potential benefits and risks of Kflam Tromethamine and other treatment options before deciding to use Kflam. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.
Acute Pain in Adult Patients
Kflam Tromethamine is indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Therapy should always be initiated with IV or IM dosing of Kflam Tromethamine, and oral Kflam Tromethamine is to be used only as continuation treatment, if necessary.
The total combined duration of use of Kflam Tromethamine injection and oral Kflam Tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses. Patients should be switched to alternative analgesics as soon as possible, but Kflam Tromethamine therapy is not to exceed 5 days.
Kflam Tromethamine injection has been used concomitantly with morphine and meperidine and has shown an opioid-sparing effect. For breakthrough pain, it is recommended to supplement the lower end of the Kflam Tromethamine injection dosage range with low doses of narcotics prn, unless otherwise contraindicated. Kflam Tromethamine injection and narcotics should not be administered in the same syringe.
How should I use Kflam?
Use Kflam spray as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Kflam spray comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Kflam spray refilled.
- Do not take Kflam spray by mouth. Use in your nose only.
- Before you use each bottle for the first time, you must prime it. Remove the clear plastic cover and the blue plastic safety clip. Hold the bottle at arm's length away from you. Using your index and middle fingers on the top of the bottle and your thumb on the bottom of the bottle, press down evenly and release the pump 5 times. The bottle is now ready to use.
- To use this nose spray, gently blow your nose. Sit up straight or stand and tilt your head forward slightly. Place the tip of the spray container into the nose. Be sure to point the container away from the center of your nose. Breathe gently through the nostril and squeeze the spray container. If your dose requires 2 sprays, repeat the process for your other nostril. Replace the clear plastic cover after each use.
- Do NOT use Kflam spray for more than 5 days. Kflam spray is not for the treatment of mild to moderate or chronic pain (eg, headache).
- Avoid contact with the eyes. If you get Kflam spray in your eyes, rinse it out with water. If eye irritation persists for more than 1 hour, contact your doctor.
- Each bottle contains 1 day's supply of Kflam spray. Discard each bottle within 24 hours of opening it, even if it still contains some unused medicine.
- If you miss a dose of Kflam spray and you are taking it regularly, take it as soon as possible. If it is almost time for the next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Kflam spray.
Uses of Kflam in details
Use: Labeled Indications
Pain, moderate to moderately severe: Short-term (up to 5 days) management of moderate to moderately severe pain in adults that requires analgesia at the opioid level.
Off Label Uses
Migraine
Data from a prospective, randomized, double-blind, double-dummy, placebo and active comparator, crossover, non-inferiority trial suggests that intranasal Kflam may be beneficial for acute abortive treatment of migraine in patients with a history of episodic migraines for at least 1 year.
Kflam description
A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of morphine. It also has a depressant action on the cough center and may be given to control intractable cough associated with terminal lung cancer. Kflam is also used as part of the treatment of dependence on opioid drugs, although prolonged use of methadone itself may result in dependence. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3)
Kflam dosage
Carefully consider the potential benefits and risks of Kflam tromethamine tablets and other treatment options before deciding to use Kflam tromethamine tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals. In adults, the combined duration of use of IV or IM dosing of Kflam tromethamine and Kflam tromethamine tablets is not to exceed 5 days. In adults, the use of Kflam tromethamine tablets is only indicated as continuation therapy to IV or IM dosing of Kflam tromethamine.
Transition from IV or IM dosing of Kflam tromethamine (single- or multiple-dose) to multiple-dose Kflam tromethamine tablets:
Patients age 17 to 64: 20 mg PO once followed by 10 mg q4 to 6 hours prn not > 40 mg/day
Patients age ≥ 65, renally impaired, and/or weight < 50 kg (110 lbs): 10 mg PO once followed by 10 mg q4 to 6 hours prn not > 40 mg/day
Note:
Oral formulation should not be given as an initial dose.
Use minimum effective dose for the individual patient.
Do not shorten dosing interval of 4 to 6 hours.
Total duration of treatment in adult patients: the combined duration of use of IV or IM dosing of Kflam tromethamine and Kflam tromethamine tablets is not to exceed 5 days.
The following table summarizes Kflam tromethamine tablet dosing instructions in terms of age group:
| Patient Population | Kflam Tromethamine Tablets (following IV or IM dosing of Kflam tromethamine) |
| Age < 17 years | Oral not approved |
| Adult Age 17 to 64 years | 20 mg once, then 10 mg q4 to 6 hours prn not > 40 mg/day |
| Adult Age ≥ 65 years, renally impaired, and/or weight < 50 kg | 10 mg once, then 10 mg q4 to 6 hours prn not > 40 mg/day |
Kflam interactions
See also:
What other drugs will affect Kflam?
Kflam slightly reduces the plasma protein-binding of warfarin. In vitro studies indicate that at therapeutic concentration of salicylate, the binding of Kflam reduces from approximately 99.2-97.5%; representing a potential 2-fold increase in unbound plasma Kflam levels. Kflam has been reported to reduce the diuretic response to furosemide in normovolemic individuals by approximately 20%.
Concomitant administration of Kflam and probenecid results in decreased clearance of Kflam and significant increase in Kflam plasma levels (approximately 3-fold increase), and there is an increase of approximately 2-fold in terminal half-life.
Increase in plasma lithium concentration due to inhibition of renal lithium clearance has been reported with some NSAIDs. There have been some reports of increased lithium plasma levels with Kflam also.
There have been reports of a possible interaction of Kflam and nondepolarizing muscle relaxants, which lead to apnea. Concomitant use of Kflam and angiotensin-converting enzyme inhibitors may increase the risk of renal impairment, particularly in volume-depleted patients.
Very few cases of seizure have been reported with concomitant use of Kflam and antiepileptic drugs (phenytoin, carbamazepine). There have been reports of hallucinations when Kflam is concomitantly used with psychoactive drugs (fluoxetine, thiothixene, alprazolam).
Laboratory Tests: Kflam inhibits platelet aggregation and may prolong bleeding time.
Food: Food reduces the rate but not the extent of absorption.
Kflam side effects
See also:
What are the possible side effects of Kflam?
Applies to Kflam ophthalmic: ophthalmic solution
In addition to its needed effects, some unwanted effects may be caused by Kflam ophthalmic. In the event that any of these side effects do occur, they may require medical attention.
Major Side Effects
You should check with your doctor immediately if any of these side effects occur when taking Kflam ophthalmic:
More common:
- Itching, redness, tearing, or other sign of eye irritation not present before use of this medicine or becoming worse during use
- redness of the clear part of the eye
- sensitivity to light
- swelling of the eye
- tearing
- throbbing pain
- Blurred vision or other change in vision
- eye irritation or redness
Minor Side Effects
Some of the side effects that can occur with Kflam ophthalmic may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:
More common:
- Stinging or burning of the eye when medicine is applied
- Dry eyes
- headache
Kflam contraindications
See also:
What is the most important information I should know about Kflam?
Kflam Tromethamine is contraindicated in patients with previously demonstrated hypersensitivity to Kflam Tromethamine.
Kflam Tromethamine is contraindicated in patients with active peptic ulcer disease, in patients with recent gastrointestinal bleeding or perforation and in patients with a history of peptic ulcer disease or gastrointestinal bleeding.
Kflam Tromethamine should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients.
Kflam Tromethamine is contraindicated as prophylactic analgesic before any major surgery.
Kflam Tromethamine is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
Kflam Tromethamine is contraindicated in patients with advanced renal impairment or in patients at risk for renal failure due to volume depletion.
Kflam Tromethamine is contraindicated in labor and delivery because, through its prostaglandin synthesis inhibitory effect, it may adversely affect fetal circulation and inhibit uterine musculature, thus increasing the risk of uterine hemorrhage.
Kflam Tromethamine inhibits platelet function and is, therefore, contraindicated in patients with suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, incomplete hemostasis and those at high risk of bleeding.
Kflam Tromethamine is contraindicated in patients currently receiving aspirin or NSAIDs because of the cumulative risks of inducing serious NSAID-related adverse events.
The concomitant use of Kflam Tromethamine and probenecid is contraindicated.
The concomitant use of Kflam Tromethamine and pentoxifylline is contraindicated.
Kflam Tromethamine injection is contraindicated for neuraxial (epidural or intrathecal) administration due to its alcohol content.
Active ingredient matches for Kflam:
Ketorolac in Bangladesh.
List of Kflam substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Keytrate | |
| Keytrate 10 mg Tablet (Wel n Drugs (Zee Laboratories Ltd)) | $ 0.04 |
| Kidoton (Taiwan) | |
| Kidoton 30 mg/1 mL x 1 mL | |
| Killpain (Taiwan) | |
| Killpain 30 mg/1 mL x 1 mL | |
| Killpain 30 mg/1 mL x 2 mL | |
| Kine (Peru) | |
| Kirtolac (Taiwan) | |
| Kirtolac 0.5 % x 5 mL | |
| Kitamass (Peru) | |
| Klenac (Argentina) | |
| KOLAC | |
| KOLAC EYE DROPS 1 packet / 5 ML eye drop each (Medivision Pharm) | $ 0.84 |
| Kolac 0.5% w/v Eye Drop (Medivision Pharm) | $ 0.84 |
| Kop (Bangladesh, Taiwan) | |
| KOP 30 mg/1 mL x 1 mL | |
| KOP 30 mg/1 mL x 2 mL | |
| Koprak (Mexico) | |
| Kortezor (Philippines) | |
| Kortezor / amp 30 mg/1 mL x 10's (Biomedis) | $ 19.90 |
| Kotonic (Bangladesh) | |
| Koxalgen (Mexico) | |
| Kroller (Italy) | |
| Ktolac (Taiwan) | |
| Ktolac 30 mg/1 mL x 1 mL | |
| Laborac | |
| Laborac 0.5% w/v EYE DPS / 5ml | $ 0.30 |
| Lacdol-S (Mexico) | |
| Lacomin (Mexico) | |
| Lactopain (Indonesia) | |
| Lactopain / amp 30 mg/1 mL x 1 mL x 5's (Lapi) | $ 16.12 |
| Lactor (Indonesia) | |
| Lactor 30 mg/1 mL x 1 mL x 6's (Phapros) | $ 18.00 |
| Landaco (Mexico) | |
| Lantipain (Indonesia) | |
| Lantipain 10 mg/1 mL x 6's (Landson) | $ 12.03 |
| Lantipain 30 mg/1 mL x 6's (Landson) | $ 17.98 |
| Laston (Taiwan) | |
| Laston 30 mg/1 mL x 1 mL | |
| Latorec (Indonesia) | |
| Legrace (Brazil) | |
| Lenaken (Mexico) | |
| Lixidol (Italy) | |
| LOKAT | |
| LOKAT 0.4% EYE DROPS 1 packet / 5 ML eye drop each (Jawa Pharmaceuticals Pvt Ltd) | $ 0.68 |
| Lokat 0.4% Eye Drop (Jawa Pharmaceuticals Pvt Ltd) | $ 0.68 |
| Lokefar (Mexico) | |
| Capsule; Oral; Ketorolac Tromethamine 10 mg | |
| Capsule; Oral; Ketorolac Tromethamine 20 mg | |
| Capsules; Oral; Ketorolac Tromethamine 10 mg | |
| Capsules; Oral; Ketorolac Tromethamine 20 mg | |
| Lopadol (Bangladesh) | |
| Lorotec (Mexico) | |
| Lorotec F (Mexico) | |
| Tablet; Sublingual; Ketorolac Tromethamine 30 mg | |
| Tablets; Sublingual; Ketorolac Tromethamine 30 mg | |
| Lupelac (Bangladesh) | |
See 936 substitutes for Kflam | |
References
- PubChem. "ketorolac". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "ketorolac". http://www.drugbank.ca/drugs/DB00465 (accessed September 17, 2018).
- MeSH. "Cyclooxygenase Inhibitors". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Kflam are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Kflam. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yet2 consumers reported age
| Users | % | ||
|---|---|---|---|
| > 60 | 1 | 50.0% | |
| 46-60 | 1 | 50.0% | |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
